Phase 1 study of immune checkpoint inhibitor Nivolumab in combination with Bezafibrate in pretreated advanced non-small cell lung cancer
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Bezafibrate (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.